Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes? - Allopurinol in LVH/Diabetes
- Conditions
- Diabetes Left Ventricular HypertrophyMedDRA version: 9.1Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)MedDRA version: 9.1Level: LLTClassification code 10049773Term: Left ventricular hypertrophy
- Registration Number
- EUCTR2008-008485-12-GB
- Lead Sponsor
- niversity of Dundee
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
Patients with diabetes
Pateints with left ventricular hypertrophy
Office target blood pressure <150/90
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Gout
Already on Allopurinol
Previous adverse reactions to Allopurinol
Poor kidney function (eGFR <60ml/min)
Conditions that exclude MRI
Heart failure
Cancer or other life threatening illness
Pregnancy or breast feeding
Unable to provide consent
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Does Allopurinol reduce left ventricular hypertrophy in diabetic patients?;Secondary Objective: Does Allopurinol reduce endothelial dysfunction in diabetic patients? ;Primary end point(s): Left ventricular hypertrophy regression on cardiac MRI<br>To see if endothelial function improves with flow mediated dilataion (FMD)<br>
- Secondary Outcome Measures
Name Time Method